Shares of Evotec SE (NASDAQ:EVO - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $4.63, but opened at $4.42. Evotec shares last traded at $4.41, with a volume of 7,333 shares traded.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of Evotec in a research report on Thursday, November 7th.
Read Our Latest Stock Analysis on Evotec
Evotec Price Performance
The firm's 50-day moving average is $4.41 and its 200-day moving average is $4.03. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.09 and a quick ratio of 1.99.
Institutional Trading of Evotec
Several hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP grew its position in Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock valued at $9,616,000 after purchasing an additional 602,858 shares during the period. DCF Advisers LLC boosted its holdings in Evotec by 5.9% during the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after acquiring an additional 12,816 shares during the last quarter. Mediolanum International Funds Ltd purchased a new position in Evotec during the 3rd quarter worth $512,000. Lighthouse Investment Partners LLC purchased a new position in Evotec during the 4th quarter worth $166,000. Finally, Clear Harbor Asset Management LLC purchased a new position in Evotec during the 3rd quarter worth $104,000. Institutional investors and hedge funds own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Read More
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
